Request more information from our team or explore ordering options and resources to bring Myriad Oncology testing into your practice.
Confirm your information below and submit the form today to schedule a meeting with a Myriad Account Executive. We can’t wait to partner with you.
You are committed to identifying the best cancer treatments for your patients. Genetic testing can provide the answers you’re looking for to create personalized medical management plans for more effective patient care.
Get the clarity you need to navigate each patient’s cancer diagnosis and treatment. Genetic testing helps you determine comprehensive cancer treatment options based on unique cancer features for each patient you treat – and increases their odds for a healthy future.
Find the right test for each patient you treat.
FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer.
Genomic prognostic test for patients newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer.
The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer.
Germline hereditary cancer test capable of identifying risk for 11 hereditary cancers.
Discover and target important variants within tumors.
A genetic test for untreated men with prostate cancer that can determine how quickly the cancer is growing and cancer recurrence risk.
Precise Oncology Solutions provides a streamlined testing experience that gives you the ability to receive comprehensive results from germline testing, tumor profiling and companion diagnostic options, including HRD† testing, with just one order.
† For patients with ovarian cancer.
* Precise Tumor, PD-L1, and FOLR1/FRα are powered by Intermountain Precision Genomics, a service of Intermountain Health. Precise Tumor and MyRisk are not approved by the FDA. FOLR1/FRα is an FDA-approved assay performed according to the intended use.
Tumor testing can identify changes in genes of cancer cells, but may present limitations including unknown variants, limited tumor tissue and missed large rearrangements. Germline testing evaluates for hereditary mutations and can inform targeted therapies and surgical decisions. Combine them both to uncover a patient’s full cancer story and create a powerful treatment plan.
Myriad has invested over 30 years in developing tests and solutions that help provide the best answers and care possible.
Our tests are:
Myriad offers industry-leading accuracy so you can feel confident in the results. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answers possible.
Myriad is committed to providing patients with access to accurate and affordable genetic results. Through excellent insurance coverage and financial assistance programs, providers and patients can feel confident knowing Myriad has options for each patient’s situation.
Myriad makes genetic testing simple with clear, actionable results. We created easy-to-understand reports to ensure that both patients and their providers can use the information to identify further treatment options based on national medical guidelines.
Myriad believes that results and genetic information belong to the patient. We take multiple steps to ensure that the security and privacy of patient data is not compromised, and we believe that patients should be in control of their information.
Come join in on open-door discussions about current topics in cancer genetics with Dr. Slavin, Myriad’s medical experts, and frequent external special guests. View the dates, times and topics below
Stay current with clinical validation and utility publications and more.
Find the Myriad documents and forms you need right here.
Intended use – PMA intended use statement for BRACAnalysis CDx
BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein-coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.
Results of the test are used as an aid in identifying patients who are or may become eligible for treatment with the targeted therapies listed in Table 1 in accordance with the most recently approved therapeutic product labeling.
Table 1: companion diagnostic indications
This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory site located at 320 Wakara Way, Salt Lake City, UT 84108
LYNPARZA is a registered trademark of the AstraZeneca group of companies.